Eldred Rock Partners LLC Has $11.31 Million Stock Holdings in Merck & Co., Inc. $MRK

Eldred Rock Partners LLC trimmed its stake in shares of Merck & Co., Inc. (NYSE:MRK) by 11.1% in the fourth quarter, HoldingsChannel reports. The firm owned 107,416 shares of the company’s stock after selling 13,464 shares during the quarter. Merck & Co., Inc. accounts for about 2.9% of Eldred Rock Partners LLC’s holdings, making the stock its 19th largest holding. Eldred Rock Partners LLC’s holdings in Merck & Co., Inc. were worth $11,307,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors and hedge funds have also recently modified their holdings of the stock. DLD Asset Management LP lifted its stake in shares of Merck & Co., Inc. by 30.1% during the 3rd quarter. DLD Asset Management LP now owns 47,500,000 shares of the company’s stock worth $3,986,675,000 after buying an additional 11,000,000 shares during the last quarter. Assenagon Asset Management S.A. grew its stake in Merck & Co., Inc. by 192.7% in the 3rd quarter. Assenagon Asset Management S.A. now owns 5,496,664 shares of the company’s stock valued at $461,335,000 after buying an additional 3,618,532 shares during the last quarter. Amundi grew its stake in Merck & Co., Inc. by 26.4% in the 2nd quarter. Amundi now owns 16,532,657 shares of the company’s stock valued at $1,363,480,000 after buying an additional 3,454,941 shares during the last quarter. Invesco Ltd. raised its holdings in Merck & Co., Inc. by 16.6% in the 3rd quarter. Invesco Ltd. now owns 19,844,936 shares of the company’s stock valued at $1,665,585,000 after acquiring an additional 2,821,766 shares during the period. Finally, Ameriprise Financial Inc. raised its holdings in Merck & Co., Inc. by 20.7% in the 3rd quarter. Ameriprise Financial Inc. now owns 15,933,909 shares of the company’s stock valued at $1,336,877,000 after acquiring an additional 2,735,459 shares during the period. 76.07% of the stock is currently owned by institutional investors and hedge funds.

Merck & Co., Inc. News Roundup

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: European approval expands KEYTRUDA use to a platinum‑resistant ovarian cancer population (PD‑L1 CPS ≥1). This label adds a new, high‑need indication and could incrementally lift oncology sales in Europe if uptake is steady; approval reduces regulatory uncertainty for the combo in that market. Merck granted EU approval of Keytruda combo in ovarian cancer
• Positive Sentiment: European Commission press release confirming KEYTRUDA + paclitaxel ± bevacizumab approval for PD‑L1‑positive, platinum‑resistant recurrent ovarian carcinoma — reinforces the commercial significance of the approval and the company’s oncology momentum in EU markets. European Commission Approves KEYTRUDA combo
• Positive Sentiment: Merck reported strong Phase 3 results for an oral PCSK9 candidate (enlicitide decanoate) — if confirmed through regulatory paths, an oral PCSK9 could be a major commercial opportunity in lipid management and compete with injectables, implying material long‑term upside to cardiovascular franchise revenue. Merck Reports Strong Phase 3 Results for Oral PCSK9
• Positive Sentiment: Initiation of a pivotal Phase 2b/3 trial for MK‑8748 (Tiespectus) in neovascular AMD shows Merck advancing a novel bispecific Tie2 agonist/VEGF inhibitor into registrational testing — de‑risks a promising ophthalmology program and could add a new specialty product if successful. Merck Announces Initiation of Pivotal Phase 2b/3 Trial
• Positive Sentiment: Royal Bank of Canada assigned an Outperform rating — analyst upgrades/support can buoy sentiment and buying interest, especially when coupled with pipeline news and recent beats. Merck Earns Outperform Rating from RBC
• Neutral Sentiment: Merck released detailed Phase 2 CADENCE data (WINREVAIR) — more granular data helps investors assess clinical profile and commercial potential, but Phase 2 detail typically moves shares less than registrational results unless outcomes are transformational. Merck Announces Detailed Results From the Phase 2 CADENCE Study
• Neutral Sentiment: Merck completed the acquisition of JSR Life Sciences’ chromatography business — broadens manufacturing/service capabilities (note: some headlines refer to Merck KGaA; confirm scope). Strategic but not immediately revenue‑moving for MRK’s core drug sales. Merck Completes Acquisition of JSR Life Sciences’ Chromatography Business
• Neutral Sentiment: Sector commentary: Lilly warned against locking pricing‑deal rules into law, citing innovation risk — a reminder of policy/regulatory uncertainty that can affect the whole pharma sector, including MRK, but it’s not a company‑specific development. Lilly Pushes Back on Making Drug Price Deals Permanent

Analyst Ratings Changes

A number of equities research analysts have recently issued reports on the company. Guggenheim boosted their price objective on Merck & Co., Inc. from $122.00 to $140.00 and gave the stock a “buy” rating in a report on Friday, February 6th. BMO Capital Markets raised Merck & Co., Inc. from a “market perform” rating to an “outperform” rating and lifted their price target for the stock from $82.00 to $130.00 in a report on Thursday, December 18th. Bank of America boosted their price target on Merck & Co., Inc. from $105.00 to $120.00 and gave the company a “buy” rating in a research note on Monday, December 15th. Wall Street Zen raised Merck & Co., Inc. from a “hold” rating to a “buy” rating in a report on Saturday, March 28th. Finally, UBS Group increased their price objective on Merck & Co., Inc. from $105.00 to $130.00 and gave the stock a “buy” rating in a research report on Wednesday, January 7th. One analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating and seven have issued a Hold rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $127.13.

Merck & Co., Inc. Stock Performance

Shares of NYSE:MRK opened at $120.62 on Friday. Merck & Co., Inc. has a 12-month low of $73.31 and a 12-month high of $125.14. The company’s 50 day moving average price is $117.47 and its two-hundred day moving average price is $102.80. The firm has a market cap of $298.21 billion, a PE ratio of 16.57, a PEG ratio of 2.44 and a beta of 0.26. The company has a quick ratio of 1.30, a current ratio of 1.54 and a debt-to-equity ratio of 0.89.

Merck & Co., Inc. (NYSE:MRK) last released its quarterly earnings results on Tuesday, February 3rd. The company reported $2.04 earnings per share for the quarter, beating analysts’ consensus estimates of $2.01 by $0.03. The company had revenue of $16.40 billion during the quarter, compared to the consensus estimate of $16.19 billion. Merck & Co., Inc. had a net margin of 28.08% and a return on equity of 44.57%. The firm’s quarterly revenue was up 5.0% on a year-over-year basis. During the same period in the previous year, the business earned $1.72 earnings per share. Merck & Co., Inc. has set its FY 2026 guidance at 5.000-5.150 EPS. Equities research analysts predict that Merck & Co., Inc. will post 9.01 earnings per share for the current year.

Merck & Co., Inc. Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, April 7th. Shareholders of record on Monday, March 16th will be issued a $0.85 dividend. The ex-dividend date of this dividend is Monday, March 16th. This represents a $3.40 annualized dividend and a yield of 2.8%. Merck & Co., Inc.’s payout ratio is currently 46.70%.

Insider Transactions at Merck & Co., Inc.

In other news, CEO Robert M. Davis sold 47,434 shares of the company’s stock in a transaction on Wednesday, February 4th. The stock was sold at an average price of $118.04, for a total transaction of $5,599,109.36. Following the completion of the sale, the chief executive officer directly owned 443,602 shares in the company, valued at approximately $52,362,780.08. This represents a 9.66% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, CFO Caroline Litchfield sold 41,997 shares of the stock in a transaction on Wednesday, February 4th. The stock was sold at an average price of $119.61, for a total value of $5,023,261.17. Following the sale, the chief financial officer directly owned 90,192 shares in the company, valued at approximately $10,787,865.12. This trade represents a 31.77% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last three months, insiders sold 320,176 shares of company stock worth $38,281,735. Corporate insiders own 0.13% of the company’s stock.

About Merck & Co., Inc.

Merck & Co, Inc is a global biopharmaceutical company engaged in the discovery, development, manufacture and marketing of prescription medicines, vaccines, biologic therapies and animal health products. Its portfolio spans multiple therapeutic areas with a particular emphasis on oncology, vaccines and infectious disease, as well as therapies for metabolic and chronic conditions. Among its well-known products are the cancer immunotherapy Keytruda (pembrolizumab) and the human papillomavirus vaccine Gardasil; the company also markets a range of medicines and vaccines for veterinary use through Merck Animal Health.

Founded in the late 19th century as the U.S.